Originally Posted by Tupelo3

Maybe it's because Teva pays higher consulting fees thank the generic manufacturers of selegilene.

In terms of the price increase, I thought Teva got the Azilect patent extended till Feb 2017. I know that Watson Labs has a generic already approved and they just had an out-of-court settlement of their patent suit. I thought they agreed on late 2016 or early 2017. That doesn't mean that generic Rasagiline will not be approved early, keeping in mind that they are different. Rasagiline, the active ingredient in Azilect, is not generic Azilect.